LAG3 and neoplasm: In preclinical murine models, combined targeting of LAG-3 and PD-1 reduced tumor growth compared with PD-1-targeted monotherapy,16 and combined anti–LAG-3 plus anti–PD-L1 therapy improved survival vs anti–PD-L1 therapy alone.17 Several LAG-3 inhibitors, including the monoclonal antibodies (mAbs) favezelimab,18 ieramilimab,19 and relatlimab,20 have also been investigated in clinical trials as monotherapy and in combination with other immune checkpoint inhibitors (ICIs), including the anti–PD-1 mAbs pembrolizumab, spartalizumab, and nivolumab, for treatment of various malignancies.